BioSpace News Archive

Deals

J&J-Backed Contineum Unveils IPO Plans to Advance MS Pipeline

Contineum Therapeutics joined the 2024 initial public offering class on Friday with an SEC filing. The biotech will use the IPO proceeds to complete a Phase II trial for its most mature candidate targeting multiple sclerosis.

March 18, 2024
·
2 min read
·
Tristan Manalac
Drug Development

GSK Builds Case for Broader Jemperli Label in Endometrial Cancer with Phase III Data

New late-stage trial results for GSK’s Jemperli show improved overall and progression-free survival in a broader range of endometrial cancer patients, which could lead to a potential label expansion.

March 18, 2024
·
2 min read
·
Tristan Manalac
Pharm Country

Pfizer to Lower Its Stake in GSK Consumer Health Spinoff Haleon

Following GSK’s lead, Pfizer plans to lower its interest in Haleon from 32% to approximately 24%, with the sale of 630 million ordinary shares in the consumer healthcare spinoff.

March 18, 2024
·
1 min read
·
Tyler Patchen
Job Trends

Report: 2024 U.S. Life Sciences Salary Trends

BioSpace’s 2024 Salary Report explores the average salaries and salary trends of life sciences professionals.

March 18, 2024
·
1 min read
·
BioSpace Insights
FDA

Madrigal’s Rezdiffra Energizes MASH Space, Sets Bar for Future Therapies

With its FDA approval last week and first-to-market advantage, Madrigal Pharmaceuticals’ Rezdiffra will set the standard for other metabolic dysfunction-associated steatohepatitis candidates in development.

March 18, 2024
·
3 min read
·
Tristan Manalac
Drug Delivery

AstraZeneca Caps US Inhaler Out-of-Pocket Costs on Heels of Boehringer

With Boehringer Ingelheim’s announcement earlier this month that it was capping U.S. inhaler costs at $35 per month, AstraZeneca on Monday followed suit.

March 18, 2024
·
2 min read
·
Tyler Patchen
Drug Development

AstraZeneca Shows Lynparza Combo Could Address Unmet Endometrial Cancer Need

AstraZeneca reported Monday that adding Lynparza to Imfinzi improved outcomes in mismatch repair proficient endometrial cancer, more than doubling the median duration of response in patients.

March 18, 2024
·
2 min read
·
Nick Paul Taylor
BioMidwest

First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference

First Wave BioPharma, Inc., announced that two abstracts have been accepted for presentation at the 2024 Digestive Disease Week Conference taking place May 18-21, 2024, in Washington, D.C.

March 18, 2024
·
6 min read
Business

Syndax Announces Appointment of Steven Closter as Chief Commercial Officer

Syndax Pharmaceuticals, a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced the appointment of Steven Closter as Chief Commercial Officer, effective immediately.

March 18, 2024
·
5 min read
BioCapital

Genseq Selects Sapio LIMS to Power Best-in-Class Next-Generation Sequencing Services

Genseq, a Dublin-based, CAP-accredited laboratory providing a range of services for biopharma and clinical research, has adopted the science-aware™ lab informatics platform from Sapio Sciences to manage its next-generation sequencing and biobanking workflows.

March 18, 2024
·
3 min read